about
Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAILRespiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligandOnto better TRAILs for cancer treatmentGetting TRAIL back on track for cancer therapyCrystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificityMechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell typesFasL gene-deficient mice display a limited disruption in spermatogenesis and inhibition of mono-(2-ethylhexyl) phthalate-induced germ cell apoptosisCoordinated regulation of two TRAIL-R2/KILLER/DR5 mRNA isoforms by DNA damaging agents, serum and 17beta-estradiol in human breast cancer cells.Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.Reovirus-induced apoptosis is mediated by TRAILSafety and antitumor activity of recombinant soluble Apo2 ligand.Tissue-specific Bcl-2 protein partners in apoptosis: An ovarian paradigm.Maternal plasma soluble TRAIL is decreased in preeclampsia.Soluble TRAIL in normal pregnancy and acute pyelonephritis: a potential explanation for the susceptibility of pregnant women to microbial products and infection.A critical role of TRAIL expressed on cotransplanted hepatic stellate cells in prevention of islet allograft rejection.CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies.Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formationThe TRAIL of oncogenes to apoptosis.Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.TRAIL/Apo-2L: mechanisms and clinical applications in cancer.Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human.Fas-independent T-cell apoptosis by dendritic cells controls autoimmune arthritis in MRL/lpr mice.Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussionDeath Receptor-Induced Apoptosis Signalling Regulation by Ezrin Is Cell Type Dependent and Occurs in a DISC-Independent Manner in Colon Cancer Cells.BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population.Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity.Complete eradication of xenograft hepatoma by oncolytic adenovirus ZD55 harboring TRAIL-IETD-Smac gene with broad antitumor effectMitochondrial inhibitor sensitizes non-small-cell lung carcinoma cells to TRAIL-induced apoptosis by reactive oxygen species and Bcl-X(L)/p53-mediated amplification mechanisms.Detection of soluble TRAIL in HBV infected patients and its clinical implications.Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression.Killing effect of TNF-related apoptosis inducing ligand regulated by tetracycline on gastric cancer cell line NCI-N87Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity.TRAIL death receptor 4 signaling via lysosome fusion and membrane raft clustering in coronary arterial endothelial cells: evidence from ASM knockout miceThe TRAIL to targeted therapy of breast cancer.The death ligand TRAIL in diabetic nephropathy.Activation of human monocytes induces differential resistance to apoptosis with rapid down regulation of caspase-8/FLICE.Therapeutic applications of TRAIL receptor agonists in cancer and beyond.Multiple sclerosis: death receptor expression and oligodendrocyte apoptosis in established lesions.Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model.Death receptors as targets for anti-cancer therapy.
P2860
Q24554360-2B0A7C80-6224-49B7-B878-707D920CC539Q24683245-BD3AB486-4052-41AF-AF9A-5C7AA1B99423Q26768160-D83C1563-A58F-4659-8C17-A5305BFF85F6Q27027460-8266AC6E-494E-4224-9E64-759D88F2FEAAQ27625357-0669E945-E97E-46F3-BF33-D043B36C92FBQ28140698-00AC7211-DD06-46D4-8C6B-B9246395E3F3Q28394309-0911932D-BB95-4D05-8508-B909E143A81FQ30896561-7D29F13A-0B36-47FE-8C36-8CB0B3ECD729Q33782305-0728A29E-C57B-4535-9BDF-28D179601144Q33810960-B836C8B2-5EED-4E94-A36A-B45D864821E9Q33855449-B01C76F4-8215-446B-90B2-B9C0540CAD60Q33881268-21E37BFF-B21A-4F02-BAC2-98630D6A0A7FQ33909572-4D9919B8-E33F-4A3F-A4C9-E1CB0FE17B0FQ33910907-FFF9644D-97B3-4F17-AC66-E8950F0EB2D0Q33941348-B9BC9F9F-8CF4-46A6-8AA5-4E7785626E65Q34266298-A8EFE6FD-4AA6-4F2A-B10B-8DD7A3BF3724Q34334395-21DD2646-58D3-4F34-9861-C4E2A121DEC8Q34354511-009562E0-9242-401C-91FD-341AAEF2FF96Q34469691-203B9ED3-5EFC-41BF-A0DB-9301DA355878Q34482821-B44FB264-E333-4E25-A95A-FB4B3038B48BQ34503355-B4B24DF6-9053-42B0-83E8-738C18E7E7EDQ34539976-8B3AAE72-E3F2-4298-BA38-F45ECD5D86FEQ35480734-73FC174E-8579-4FC7-A0D1-3BE29D2C1419Q35641622-601A7C08-5649-4BC3-A508-6B5B4263DEAAQ35834649-36C66496-BBCB-4AD7-97AB-EED0B15253B8Q35855534-0B09D376-FC93-4B13-AD7B-00EC050E5CC4Q36228905-C03DA874-5398-479E-95C6-8C789EF05278Q36292039-C2DB7B6F-4514-415E-8EAE-7ED683285A93Q36308409-069FA612-6F85-4286-9413-E6E4BEB0AF0BQ36368539-70AF268F-194E-448A-A5B5-04E582FE8803Q36397251-8C95B081-9C37-4778-8E4A-E60D67002DF3Q36400613-B5AD4BCB-24EA-48FC-A8E4-C38746DA29C9Q36511154-DFE07BBB-7683-4B65-BAF8-727A57AE19D1Q36511919-23CF313E-71AE-45AF-80D3-4E41C957455CQ36662104-D45B0DF5-E9AC-45FC-8D06-D97FCB894473Q36733758-DE3BB6CE-8193-4BA1-96ED-D8F162D58667Q37114025-3BE8F581-0BB8-4888-9B95-2B7DDB675A55Q37258257-13D5F1DE-916D-40D2-A6F8-9E56338C2AD4Q37310677-E3D346FA-D8FC-4F7A-AFB4-765A75B2DF42Q37390893-6AF02333-0669-4F89-BC34-86C983C1F4A4
P2860
description
1997 nî lūn-bûn
@nan
1997 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Characterization of two receptors for TRAIL
@ast
Characterization of two receptors for TRAIL
@en
Characterization of two receptors for TRAIL
@en-gb
Characterization of two receptors for TRAIL
@nl
type
label
Characterization of two receptors for TRAIL
@ast
Characterization of two receptors for TRAIL
@en
Characterization of two receptors for TRAIL
@en-gb
Characterization of two receptors for TRAIL
@nl
prefLabel
Characterization of two receptors for TRAIL
@ast
Characterization of two receptors for TRAIL
@en
Characterization of two receptors for TRAIL
@en-gb
Characterization of two receptors for TRAIL
@nl
P2093
P2860
P921
P1433
P1476
Characterization of two receptors for TRAIL
@en
P2093
P2860
P304
P356
10.1016/S0014-5793(97)01231-3
P407
P50
P577
1997-10-27T00:00:00Z